Related Experiment Video
Updated: Sep 11, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns
Yitian Zhang1, Xiaomeng Dai2, Jinzi Liang3
1Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China; The Graduate Training Base of Zhejiang Provincial People's Hospital affiliated with Jinzhou Medical University, Jinzhou, Liaoning, China; Department of Oncology, Jinxiang People's Hospital, Jinxiang, Shandong, China.
Background:
Patients withEGFR-sensitizing mutations in non-small cell lung cancer (NSCLC) predominantly receive first-line tyrosine kinase inhibitors (TKIs). Subsequent TKI resistance manifests through heterogeneous clinicopathological features, including distinct resistance subtypes (primary vs. acquired),PD-L1expression levels, and molecular profiles from re-biopsies. While immunotherapy represents a potential subsequent option, the predictive biomarkers guiding optimal patient selection remain undefined.
Patients And Methods:
This multicenter retrospective study analyzed 1,396 EGFR-mutant NSCLC patients from five Chinese institutions, with 312 meeting stringent inclusion criteria. Comprehensive treatment data encompassing EGFR-TKIs, platinum-based chemotherapy, anti-angiogenic agents, and immune checkpoint inhibitors (ICIs) were collected. Cox proportional hazards regression identified progression-free survival (PFS)-associated variables, enabling resistance subtyping. Comparative effectiveness analyses across therapeutic modalities were performed.
Results:
Multivariable Cox regression identified two independent predictors of immunotherapy PFS:EGFRmutation subtypes (exon21 L858R vs. exon19del; HR 0.84, 95 % CI [0.70-0.99], P = 0.042) and TKI resistance classification (acquired vs. primary: HR 2.28, 95 % CI [1.52-3.43], P = 0.001). Patients with primary TKI resistance showed improved outcomes with ICIs (median PFS 8.5 vs. 4.0 months; HR 0.46,95 % CI [0.29-0.76], P = 0.002), particularly in L858R-mutant subgroups. In contrast, acquired resistance cohorts-especially those with exon19del mutations-derived limited clinical benefit (HR 1.09, 95 % CI [0.84-1.42];P = 0.510). These findings suggest that resistance subtype and mutation profile may aid immunotherapy selection in EGFR-mutant NSCLC, requiring validation through prospective studies.
Conclusions:
This multicenter analysis demonstrates that immunotherapy outcomes in EGFR-mutant NSCLC after TKI failure are influenced by both resistance subtypes (primary vs. acquired) and specific EGFR mutation profiles (L858R vs. exon19del). Patients with primary resistance and L858R mutations derive clinically meaningful benefit from ICIs, while those with acquired resistance, particularly exon19del variants, showed limited efficacy. These findings support further investigation of resistance-phenotype-guided therapeutic algorithms in prospective trials to optimize treatment sequencing strategies.
Insights
For EGFR-mutant non-small cell lung cancer patients who fail tyrosine kinase inhibitors (TKIs), immunotherapy outcomes depend on resistance type and EGFR mutation. Primary resistance with L858R mutations benefits most from immunotherapy.
Area of Science:
- Oncology
- Translational Research
- Lung Cancer
Background:
- EGFR-mutant non-small cell lung cancer (NSCLC) patients typically receive tyrosine kinase inhibitors (TKIs).
- TKI resistance is complex, with varied subtypes and molecular profiles.
- Predictive biomarkers for immunotherapy after TKI failure in NSCLC are needed.
Purpose of the Study:
- To investigate the impact of EGFR mutation subtypes and TKI resistance mechanisms on immunotherapy efficacy in NSCLC.
- To identify predictive biomarkers for selecting optimal immunotherapy strategies post-TKI treatment.
Main Methods:
- Retrospective analysis of 1,396 EGFR-mutant NSCLC patients from five Chinese institutions.
- Collected comprehensive treatment data including TKIs, chemotherapy, anti-angiogenic agents, and immune checkpoint inhibitors (ICIs).
- Used Cox regression to identify progression-free survival (PFS)-associated variables and classify resistance subtypes.
Main Results:
- EGFR mutation subtype (L858R vs. exon19del) and TKI resistance (primary vs. acquired) independently predicted immunotherapy PFS.
- Patients with primary TKI resistance showed significantly improved outcomes with ICIs (median PFS 8.5 vs. 4.0 months).
- Acquired resistance, especially with exon19del mutations, demonstrated limited clinical benefit from ICIs.
Conclusions:
- Immunotherapy outcomes in EGFR-mutant NSCLC post-TKI failure are influenced by resistance subtype and EGFR mutation profile.
- Primary resistance and L858R mutations predict meaningful benefit from ICIs.
- Acquired resistance, particularly exon19del variants, shows limited ICI efficacy, warranting further prospective validation.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Related Concept Videos
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...